Investigating the Inotropic Potential of Apelin (INO-apelin)
Primary Purpose
Heart Failure
Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Apelin
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Heart Failure focused on measuring Apelin, Heart failure, Pulmonary artery pressure, Inotropic, Diuretic
Eligibility Criteria
Inclusion Criteria:
Healthy volunteers:
>18yrs
Heart failure patients;
- New York Heart Failure class II-IV
- Ejection fractional <35% or fractional shortening <20% within previous 6months.
Exclusion Criteria:
All subjects,
- Females of child bearing age not on adequate contraception
- Lack of informed consent
- Age <18yrs
- Current involvement in any other research study
- Systolic BP >190 or <100
- Malignant arrhythmias
- Renal or hepatic failure
- Haemodynamically significant aortic stenosis
- Severe or significant co-morbidity
- Pacemakers
Healthy volunteers
- Any regular medication
- Previous history of any cardiovascular disease
Sites / Locations
- Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France CrescRecruiting
- Gareth BarnesRecruiting
- University of EdinburghRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Apelin infusion
Placebo
Arm Description
6 hour infusion of apelin peptide into circulation
Infusion of saline into systemic circulation
Outcomes
Primary Outcome Measures
cardiac output
We will assess, using thoracic bioimpedance cardiography, the change in cardiac output in response to apelin infusion
Secondary Outcome Measures
Urine volume
All urine will be collected during the studya and we will assess volume and relevant biochemical/humoral factors
Pulmonary artery pressure
Using echocardiography we will estimate the pulmaonary artery pressure from pulmonary velocity and assess any change during the first hour of study.
Full Information
NCT ID
NCT01179061
First Posted
August 9, 2010
Last Updated
January 13, 2011
Sponsor
University of Edinburgh
1. Study Identification
Unique Protocol Identification Number
NCT01179061
Brief Title
Investigating the Inotropic Potential of Apelin
Acronym
INO-apelin
Official Title
Investigating the Inotropic Potential of Apelin in Healthy Volunteers and Patients With Chronic Stable Heart Failure
Study Type
Interventional
2. Study Status
Record Verification Date
August 2010
Overall Recruitment Status
Unknown status
Study Start Date
August 2010 (undefined)
Primary Completion Date
August 2011 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
University of Edinburgh
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The apelin-APJ system is a recently discover hormone system that has several important actions in the cardiovascular system. Apelin causes the heart pump with more force and also causes blood vessels to relax. Studies to date show that people with reduced pumping function of the heart have lower levels of apelin in the bloodstream compared to people with normal heart function. We have previously given apelin to healthy volunteers and people with reduced pumping function and this increases the heart's contraction. However, this has only been assessed over a short time period, around fifteen minutes, and we now want to know if this effect is seen over a longer period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
Keywords
Apelin, Heart failure, Pulmonary artery pressure, Inotropic, Diuretic
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
24 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Apelin infusion
Arm Type
Experimental
Arm Description
6 hour infusion of apelin peptide into circulation
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Infusion of saline into systemic circulation
Intervention Type
Drug
Intervention Name(s)
Apelin
Intervention Description
Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.
Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.
Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
Primary Outcome Measure Information:
Title
cardiac output
Description
We will assess, using thoracic bioimpedance cardiography, the change in cardiac output in response to apelin infusion
Time Frame
6 hours
Secondary Outcome Measure Information:
Title
Urine volume
Description
All urine will be collected during the studya and we will assess volume and relevant biochemical/humoral factors
Time Frame
6 hours
Title
Pulmonary artery pressure
Description
Using echocardiography we will estimate the pulmaonary artery pressure from pulmonary velocity and assess any change during the first hour of study.
Time Frame
1 hour
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy volunteers:
>18yrs
Heart failure patients;
New York Heart Failure class II-IV
Ejection fractional <35% or fractional shortening <20% within previous 6months.
Exclusion Criteria:
All subjects,
Females of child bearing age not on adequate contraception
Lack of informed consent
Age <18yrs
Current involvement in any other research study
Systolic BP >190 or <100
Malignant arrhythmias
Renal or hepatic failure
Haemodynamically significant aortic stenosis
Severe or significant co-morbidity
Pacemakers
Healthy volunteers
Any regular medication
Previous history of any cardiovascular disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gareth D Barnes, MBChB
Phone
00447967621980
Email
gareth.barnes@ed.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Alan G Japp, MBChB
Email
alangjapp@hotmail.com
Facility Information:
Facility Name
Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc
City
Edinburgh
ZIP/Postal Code
EH16 4SA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gareth D Barnes, MBChB
Phone
00447967621980
Email
gareth.barnes@ed.ac.uk
First Name & Middle Initial & Last Name & Degree
Alan Japp, MBChB
First Name & Middle Initial & Last Name & Degree
Christian M Pedersen, MD
First Name & Middle Initial & Last Name & Degree
Nicholas A Boon, MBBChir,MD
First Name & Middle Initial & Last Name & Degree
David E Newby, BM, PhD, DM
First Name & Middle Initial & Last Name & Degree
Martin Denvir, MBChB, PhD
Facility Name
Gareth Barnes
City
Edinburgh
ZIP/Postal Code
EH16 4SA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gareth D Barnes, MBChB
Phone
00447967621980
Email
gareth.barnes@ed.ac.uk
First Name & Middle Initial & Last Name & Degree
Alan G Japp, MBChB
Email
alanglanjapp@hotmail.co.uk
Facility Name
University of Edinburgh
City
Edinburgh
ZIP/Postal Code
EH16 4SA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gareth D Barnes, MBChB
Email
gareth.barnes@ed.ac.uk
First Name & Middle Initial & Last Name & Degree
Gareth D Barnes, MBCHB
12. IPD Sharing Statement
Citations:
PubMed Identifier
23519586
Citation
Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, Veitch S, Jeong H, White A, Cruden NL, Huson L, Japp AG, Newby DE. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013 May;6(3):482-91. doi: 10.1161/CIRCHEARTFAILURE.111.000077. Epub 2013 Mar 21.
Results Reference
derived
Learn more about this trial
Investigating the Inotropic Potential of Apelin
We'll reach out to this number within 24 hrs